As a result of the elevated circulating levels of PDGF-BB and the presence of PDGFR-β in the tumor, the patient was started on imatinib mesylate (400 mg/day) in early October 2004. After 6 days ...
The authors noted that PDGFR-stimulatory antibodies did not completely replicate the effects of PDGF: they hypothesize that these autoantibodies generate a more persistent stimulus than PDGF does.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback